GreyBird Ventures

NeuoKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Platomics is a Vienna-based company specialized in regulatory automation and the design, development, manufacture and operation of digital in vitro diagnostic medical devices. Our PlatoX platform offers a secure cloud platform, innovative software solutions and a network for the exchange of information, products and services for the IVD industry. We develop compliant, high performance analysis services for genetic testing, which can also be used by manufacturers and labs to set up their own compliant products.

GNA Biosolutions is a molecular technology company based in Martinsried, Germany. Their breakthrough technology, Pulse Controlled Amplification, transforms molecular testing by combining ultrafast nucleic acid amplification with intrinsic sample prep, to enable powerful solutions for the laboratory, on-site applications and the Point of Care. Their vision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere.

Jiangxi Zhongke Jiufeng Wisdom Medical Technology Co., Ltd. was established in May 2015. Under the strong support of the Jiangxi Provincial Party Committee Government, Nanchang Municipal Government and the High-tech Zone Government, the former Siemens Northeast Asia (Greater China + Korea) Medical Mr. Wu Wenhui, the president, led the team of domestic and international first-class science and technology experts, hospital management experts and industry senior professional managers.

Ceres Nanosciences Inc. (“Ceres”) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology, which captures, enriches and preserves analytes/biomarkers. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres has a broad product pipeline of advanced sample collection technologies and diagnostics, funded through federal agency grants and industry collaboration funding. Ceres’ lead product in development is a direct antigen test for the diagnosis of Lyme disease, which will be available commercially in 2015.

Atlas5D is a leader in creating solutions to help people with reduced mobility live better and richer lives. These populations range in age from very young to very old; cover a wide variety of conditions, such as multiple sclerosis and Parkinson's; and often do not or cannot use "wearable" sensors. Our product, Echo5D, is the world's first ambient sensor that sits passively on a shelf and precisely measures human movement and behavior, 24x7, even in the dark. There's nothing to remember, no need to wear any devices, no change in lifestyle, and no photos. By providing insight and quantitative actionable information to caregivers and clinicians, we offer people with reduced mobility the ability to track progression and response of symptoms, and the confidence and opportunity to live independently. Our founders are MIT graduates with experience at McKinsey, Exponent, and Harvard Medical School; mentors include luminaries from Harvard Business School, Siemens, and MIT. Atlas5D is an alumnus of MassChallenge and TechStars. Please visit us at www.atlas5d.com.